Literature DB >> 27643399

Effects of testosterone on the transgender male voice.

M S Irwig1, K Childs2, A B Hancock2.   

Abstract

There is sparse prospective data on the effects of testosterone therapy on the voices of transgender men (also referred to as trans men or female-to-male transsexuals). Our aim was to investigate the timing and degree of voice deepening over 12 months among an ethnically diverse sample of transgender men. This was a prospective 12-month study at an academic outpatient endocrinology clinic and speech and voice center. The participants were seven transgender men naïve to testosterone therapy. All patients received two voice assessments at baseline and one assessment at 3, 6, 9, and 12 months while on intramuscular testosterone esters. Serum testosterone and estradiol concentrations were measured at baseline and every 3 months. All seven transgender men reached a cisgender male mean fundamental frequency (MF0) within 6 months of testosterone therapy and four continued to experience a decrease after 6 months. The mean decrease in MF0 after 12 months of testosterone therapy was 6.4 semitones (49 Hz). Several patterns emerged regarding the extent and timing. For example, some participants showed no decrease in MF0 within the first 3 months of testosterone therapy, whereas others showed their greatest decrease in MF0. We concluded that transgender men who start testosterone therapy display different patterns of voice lowering. Clinicians should counsel transgender men that they may or may not experience voice lowering within the first 3 months of testosterone therapy and that the majority of voice deepening will occur within 6-9 months.
© 2016 American Society of Andrology and European Academy of Andrology.

Entities:  

Keywords:  androgen; testosterone; transgender; transsexual; voice

Mesh:

Substances:

Year:  2016        PMID: 27643399     DOI: 10.1111/andr.12278

Source DB:  PubMed          Journal:  Andrology        ISSN: 2047-2919            Impact factor:   3.842


  9 in total

1.  SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people.

Authors:  A D Fisher; G Senofonte; C Cocchetti; G Guercio; V Lingiardi; M C Meriggiola; M Mosconi; G Motta; J Ristori; A M Speranza; M Pierdominici; M Maggi; G Corona; F Lombardo
Journal:  J Endocrinol Invest       Date:  2021-10-22       Impact factor: 4.256

2.  Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.

Authors:  E Coleman; A E Radix; W P Bouman; G R Brown; A L C de Vries; M B Deutsch; R Ettner; L Fraser; M Goodman; J Green; A B Hancock; T W Johnson; D H Karasic; G A Knudson; S F Leibowitz; H F L Meyer-Bahlburg; S J Monstrey; J Motmans; L Nahata; T O Nieder; S L Reisner; C Richards; L S Schechter; V Tangpricha; A C Tishelman; M A A Van Trotsenburg; S Winter; K Ducheny; N J Adams; T M Adrián; L R Allen; D Azul; H Bagga; K Başar; D S Bathory; J J Belinky; D R Berg; J U Berli; R O Bluebond-Langner; M-B Bouman; M L Bowers; P J Brassard; J Byrne; L Capitán; C J Cargill; J M Carswell; S C Chang; G Chelvakumar; T Corneil; K B Dalke; G De Cuypere; E de Vries; M Den Heijer; A H Devor; C Dhejne; A D'Marco; E K Edmiston; L Edwards-Leeper; R Ehrbar; D Ehrensaft; J Eisfeld; E Elaut; L Erickson-Schroth; J L Feldman; A D Fisher; M M Garcia; L Gijs; S E Green; B P Hall; T L D Hardy; M S Irwig; L A Jacobs; A C Janssen; K Johnson; D T Klink; B P C Kreukels; L E Kuper; E J Kvach; M A Malouf; R Massey; T Mazur; C McLachlan; S D Morrison; S W Mosser; P M Neira; U Nygren; J M Oates; J Obedin-Maliver; G Pagkalos; J Patton; N Phanuphak; K Rachlin; T Reed; G N Rider; J Ristori; S Robbins-Cherry; S A Roberts; K A Rodriguez-Wallberg; S M Rosenthal; K Sabir; J D Safer; A I Scheim; L J Seal; T J Sehoole; K Spencer; C St Amand; T D Steensma; J F Strang; G B Taylor; K Tilleman; G G T'Sjoen; L N Vala; N M Van Mello; J F Veale; J A Vencill; B Vincent; L M Wesp; M A West; J Arcelus
Journal:  Int J Transgend Health       Date:  2022-09-06

Review 3.  The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.

Authors:  Marià Alemany
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

4.  Organizing the voice questionnaire for transgender persons.

Authors:  Charlotte Bultynck; Charlotte Pas; Justine Defreyne; Marjan Cosyns; Guy T'Sjoen
Journal:  Int J Transgend Health       Date:  2019-05-08

5.  Longitudinal Case Study of Transgender Voice Changes Under Testosterone Hormone Therapy.

Authors:  Gabriel J Cler; Victoria S McKenna; Kimberly L Dahl; Cara E Stepp
Journal:  J Voice       Date:  2019-04-13       Impact factor: 2.009

6.  Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.

Authors:  Milou Cecilia Madsen; Dennis van Dijk; Chantal Maria Wiepjes; Elfi Barbara Conemans; Abel Thijs; Martin den Heijer
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

7.  Listener Age and Gender Diversity: Effects on Voice-based Perception of Gender.

Authors:  Katherine M Brown; Kimberly L Dahl; Gabriel J Cler; Cara E Stepp
Journal:  J Voice       Date:  2020-03-09       Impact factor: 2.300

8.  Testosterone therapy masculinizes speech and gender presentation in transgender men.

Authors:  Carolyn R Hodges-Simeon; Graham P O Grail; Graham Albert; Matti D Groll; Cara E Stepp; Justin M Carré; Steven A Arnocky
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

9.  Mapping evidence on the effects of gender-affirming hormone therapy on the hard and soft tissues of the craniofacial complex in transgender people: a protocol for a scoping review.

Authors:  M F Van den Bosch; C M Wiepjes; M Den Heijer; L J Schoonmade; R E G Jonkman; R A Meursinge Reynders
Journal:  Syst Rev       Date:  2021-04-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.